Riskpilot← Back to searchSign inGet full accessEndothel Pharma ApS
APSActiveCVR 37988936Frederiksgade 19, 3.Manufacture of pharmaceutical preparations · NACE 2120Est. 2016— employees
Revenue 2025
DKK -44K
+3% vs 2024
EBITDA margin
100.0%
-3% vs 2024
Equity ratio
-82.2%
Financial strength
Net profit 2025
DKK -87K
-7% vs 2024
| Revenue | DKK -44K | +3% |
| EBITDA | DKK -44K | -3% |
| Net profit | DKK -87K | -7% |
| Total assets | DKK 563K | -2% |
| Equity | DKK -463K | -23% |
| Employees | — | — |
Legal name
Endothel Pharma ApS
CVR number
37988936
Legal form
Anpartsselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
31. august 2016
Share capital
DKK 75.000
Employees
—
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren.
Company purpose
Selskabets formål er at udvikle lægemidler samt dermed beslægtet virksomhed
Address
Frederiksgade 19, 3.
Email
sisse.ostrowski@gmail.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -29 | -53 | -23 | -13 | -25 | -48 | -57 | -42 | -44 |
| Staff expenses | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBITDA | -29 | -53 | -23 | -13 | -25 | -48 | -57 | -42 | -44 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | -29 | -53 | -23 | -13 | -25 | -48 | -57 | -42 | -44 |
| Net financials | -2 | -6 | -13 | -16 | -21 | -28 | -34 | -39 | -43 |
| Profit before tax | -31 | -59 | -36 | -29 | -47 | -76 | -91 | -82 | -87 |
| Tax | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| Net profit | -31 | -59 | -36 | -29 | -47 | -76 | -91 | -82 | -87 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | 74 | 302 | 331 | 368 | 543 | 555 | 559 | 575 | 563 |
| Equity | 19 | -40 | -52 | -80 | -127 | -203 | -294 | -376 | -463 |
| Long-term debt | 0 | 12 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 55 | 342 | 383 | 449 | 670 | 758 | 853 | 951 | 1.026 |
| Total debt | 55 | 342 | 383 | 449 | 670 | 758 | 853 | 951 | 1.026 |
EBITDA margin
-4353600.0%
This company
15.8%
Market median
-27554530% vs market
20172025
Equity ratio
-82.2%
This company
38.2%
Market median
-315% vs market
20172025
Return on equity
-8700600.0%
This company
18.4%
Market median
-47285970% vs market
20172025
Net profit margin
-8700600.0%
This company
8.1%
Market median
-107414915% vs market
20172025
Asset turnover
-0.08×
This company
1.12×
Market median
-107% vs market
20172025
Debt / equity
2.22×
This company
0.62×
Market median
-258% vs market
20172025
- Annual report 2025Filed via CVR / Virk · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via CVR / Virk · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via CVR / Virk · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via CVR / Virk · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via CVR / Virk · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via CVR / Virk · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via CVR / Virk · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via CVR / Virk · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via CVR / Virk · Period 2016-08-31 – 2017-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
LH Founder | Founder | 2016 | — | — |
SR Founder | Founder | 2016 | — | — |
RS Management | Management | 2026 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2016 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 50.0% | 66.7% | 2026 | |
| Individual | 50.0% | 66.7% | 2026 | |
| Individual | 50.0% | 25.0% | 2026 | |
DocSRO ApS | Company | 33.3% | 50.0% | 2019 |
| Individual | 33.3% | 50.0% | 2019 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Endothel Pharma ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Leif Helth Jensen | Founder | 0 companies |
| Sisse Rye Ostrowski | Founder | 0 companies |
| Rikke Stine Friis Fléron | Management | 0 companies |
| Pär Ingemar Johansson | Board of Directors | 0 companies |